FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Advancing Fibroblast Therapy on Multiple Fronts In the past month, ...

FibroBiologics, Inc., a biotechnology company focused on developing therapies for chronic diseases using fibroblasts, announced that Dr. Chuo Fang presented research at the Society for Investigative ...

FibroBiologics Inc. FBLG on Tuesday said it completed manufacturing of the first batch of FibroBiologics' proprietary CYWC628 ...

FibroBiologics, Inc., (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development of therapeutics and potential cures ...

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on ...

HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with 270+ patents issued and pending with a focus on the development ...

FibroBiologics, Inc., a clinical-stage biotechnology company focused on developing therapies for chronic diseases through fibroblasts, announced an investor webinar scheduled for July 10, 2025, at ...

HOUSTON, March 02, 2026 (GLOBE NEWSWIRE) -- FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics” or the “Company”), a clinical-stage biotechnology company with 270+ patents issued and pending with a ...

H.C. Wainwright analyst Matthew Caufield reiterated a Buy rating on FibroBiologics, Inc. (FBLG – Research Report) today and set a price target of $12.00. Matthew Caufield has given his Buy rating due ...